BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

PURPOSE: BRCA1/2 mutations are frequent in patients with triple-negative breast cancer (TNBC). These patients are often treated with primary systemic chemotherapy. The aim of this study was to analyze the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (D...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Fasching, Peter A., Loibl, Sibylle, Hu, Chunling, Hart, Steven N., Shimelis, Hermela, Moore, Raymond, Schem, Christian, Tesch, Hans, Untch, Michael, Hilfrich, Jörn, Rezai, Mahdi, Gerber, Bernd, Costa, Serban Dan, Blohmer, Jens-Uwe, Fehm, Tanja, Huober, Jens, Liedtke, Cornelia, Weinshilboum, Richard M., Wang, Liewei, Ingle, James N., Müller, Volkmar, Nekljudova, Valentina, Weber, Karsten E., Rack, Brigitte, Rübner, Matthias, von Minckwitz, Gunter, Couch, Fergus J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2018
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067803/
https://ncbi.nlm.nih.gov/pubmed/29791287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.2285
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars